Compare CLNN & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLNN | ANIX |
|---|---|---|
| Founded | 2012 | 1982 |
| Country | United States | United States |
| Employees | 79 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.7M | 88.8M |
| IPO Year | N/A | 2013 |
| Metric | CLNN | ANIX |
|---|---|---|
| Price | $6.07 | $2.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $33.75 | $8.67 |
| AVG Volume (30 Days) | ★ 671.8K | 94.4K |
| Earning Date | 05-08-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 12.82 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $210,000.00 |
| Revenue This Year | $17.64 | N/A |
| Revenue Next Year | $19,516.77 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.25 | $2.44 |
| 52 Week High | $13.50 | $5.46 |
| Indicator | CLNN | ANIX |
|---|---|---|
| Relative Strength Index (RSI) | 44.04 | 40.80 |
| Support Level | $5.56 | $2.65 |
| Resistance Level | $6.92 | $3.12 |
| Average True Range (ATR) | 0.53 | 0.12 |
| MACD | -0.10 | -0.02 |
| Stochastic Oscillator | 14.69 | 20.51 |
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.